Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HeartFlowHTFL +0.07%12 Days Sales Outstanding is 56.28 as of Mar. 2026, which is 14% below its 10-year median of 65.55. GuruFocus rates HTFL with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 655 Healthcare Providers & Services companies, HeartFlow ranks worse than 60.76% on this metric.
HeartFlow's average Accounts Receivable for the
three
months ended in Mar. 2026 was $32.4 Mil. HeartFlow's Revenue for the
three
months ended in Mar. 2026 was $52.6 Mil.
Hence, HeartFlow's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 56.28.
The historical rank and industry rank for HeartFlow's Days Sales Outstanding or its related term are showing as below:
HTFL'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.96 Med: 65.55 Max: 86.03
Current: 57.48
During the past 3 years, HeartFlow's highest Days Sales Outstanding was 86.03. The lowest was 55.96. And the median was 65.55.
HTFL's Days Sales Outstanding is ranked worse than 60.76% of 655
companies
in the Healthcare Providers & Services industry
Industry Median: 47.19
vs HTFL: 57.48
HeartFlow's Days Sales Outstanding
declined
from Mar. 2025 (64.93) to Mar. 2026 (56.28).
HeartFlow (NAS:HTFL) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
HeartFlow Days Sales Outstanding Related Terms
HeartFlow Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for HeartFlow's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HTFL vs OMCL, TDOC, OMDA: Days Sales Outstanding Comparison
For the Health Information Services subindustry, HeartFlow's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeartFlow Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, HeartFlow's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where HeartFlow's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeartFlow (HTFL) has a Days Sales Outstanding of 56.28 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on HeartFlow and its competitors. This is 14% below median its historical median of 65.55. Over the past decade, HeartFlow's Days Sales Outstanding has ranged from 55.96 to 86.03. According to the industry distribution chart, HeartFlow ranks #398 out of 655 companies in the Healthcare Providers & Services industry, placing it in the top 60.8%.
Is HeartFlow's Days Sales Outstanding too high?
HeartFlow's current Days Sales Outstanding of 56.28 is 14% below median its 10-year median of 65.55. Over the past 10 years, this metric has ranged from a low of 55.96 to a high of 86.03. The Healthcare Providers & Services industry median Days Sales Outstanding is 47.19. HeartFlow's value of 56.28 is 19.3% above this industry median. Based on the distribution chart, HeartFlow ranks #398 out of 655 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, HeartFlow has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does HeartFlow's Days Sales Outstanding compare to OMCL and TDOC?
According to the Healthcare Providers & Services industry distribution chart, HeartFlow ranks #398 out of 655 companies for Days Sales Outstanding. This places HeartFlow in the lower half of its industry. The industry median Days Sales Outstanding is 47.19. HeartFlow's value of 56.28 is 19.3% above this benchmark. Historically, HeartFlow's own Days Sales Outstanding has ranged from 55.96 to 86.03 over the past decade. While the company's 10-year median is 65.55 vs. the industry median of 47.19, HeartFlow has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 47.19, based on 655 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HeartFlow's current Days Sales Outstanding of 56.28 is 19.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on HeartFlow and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 47.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeartFlow's current Days Sales Outstanding is 56.28, which is 14% below median its own 10-year median of 65.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeartFlow stock overvalued right now?
HeartFlow (HTFL) has a current Days Sales Outstanding of 56.28. The current Days Sales Outstanding is 56.28, which is 14% below median its 10-year median of 65.55 and 19.3% above the Healthcare Providers & Services industry median of 47.19. HeartFlow's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For HeartFlow (HTFL), the current Days Sales Outstanding is 56.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
12GF Score
Get the complete analysis for HTFL
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HTFL has been successfully added to your 
